Phase 1 Study of MDX-1401 in Patients With CD30-positive Refractory/Relapsed Hodgkin's Lymphoma

To establish the safety and tolerability profile of MDX-1401 in patients with relapsed or refractory Hodgkin's Lymphoma (HL).

Lead sponsor: Bristol-Myers Squibb•6 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Start Free Trial

Related studies

COMPLETEDEARLY Phase 1

p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies

NCT02846935 · T-cell Lymphoma, Aggressive B-cell Lymphoma, and more

TERMINATEDPhase 3

Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas

NCT01732926 · Indolent Non-Hodgkin's Lymphomas

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: December 6, 2012Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE1

Enrollment22

Start dateFeb 2008

Last updatedDec 6, 2012

Condition

Hodgkin's Lymphomas

Locations shown

Winship Cancer Institute, Emory University

Atlanta, Georgia

Northwestern University Feinberg School of Medicine

Chicago, Illinois

Memorial Sloan Kettering Cancer Center

New York, New York

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 6, 2012Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions